<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894153</url>
  </required_header>
  <id_info>
    <org_study_id>rAd-p53-001</org_study_id>
    <nct_id>NCT00894153</nct_id>
  </id_info>
  <brief_title>p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage</brief_title>
  <official_title>Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen SiBiono GeneTech Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen SiBiono GeneTech Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicenter, open-label, randomized, active-controled, phase IV study of local direct
      intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , with concurrent
      radiotherapy, or combination with surgery for treatment of head and neck malignant tumors in
      advanced stage .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objectives of this study is to determine the efficacy profiles of rAd-p53 intra-tumor
      injection alone, with concurrent chemotherapy, with concurrent radiotherapy, or combination
      with surgery for treatment of head and neck malignant tumors in advanced stage (stage III or
      IV) including target lesion complete response rate (LCR) and overall target lesion response
      rate (OLR), response duration (RD), and progress-free survival (PFS).

      The secondary objectives of this study is to investigate overall response rate (OPCR) and
      overall complete response rate (OCR), overall survival (OS), ECOG, and safety of rAd-p53
      monotherapy and combined with chemotherapy, radiotherapy or surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>chemo plus p53</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemotherapy plus p53</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemo only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>chemotherapy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radio</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy plus p53</intervention_name>
    <description>chemotherapy plus p53</description>
    <arm_group_label>chemo plus p53</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
    <description>chemotherapy</description>
    <arm_group_label>chemo only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>radiotherapy</description>
    <arm_group_label>radio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced stages of head and neck malignant tumors (stage III and VI)

          2. At least one target tumor can be injected with study drug, the largest diameter
             greater than 2 cm

          3. Histologically confirmed head and neck malignant tumors

          4. No prior chemotherapy, radiotherapy or biological tumor therapy in 2 weeks

          5. Age: 18-85 years old

          6. Expected to survive more 12 weeks

          7. ECOG:0-2

          8. Neutrophils≥1.5×109/L,Platelet≥ 80×109/L, Hb≥80g/L, bilitubin≤2mg/dl,ALT and AST
             ≤2×institutional upper limit of normal, Cr ≤1.5×institutional upper limit of
             normal,coagulation tests (PTT and INR) within normal range

          9. Subject provided signed informed consent

        Exclusion Criteria:

          1. Hypersensitive to study drug

          2. Tumor(s) locate very close to important blood vessels and nerves, which affect
             injection

          3. With a coagulation and bleeding disorder

          4. With uncontrolled, intercurrent illness including but limited to symptomatic
             neurological illness, symptomatic congestive heart failure, unstable angina pectoris,
             significant pulmonary disease or hypoxia, or psychiatric illness

          5. Local infection close to injection site or systemic infection

          6. Pregnant or lactating

          7. Principle investigator consider not suitable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Longjiang Li, PhD</last_name>
    <phone>86-28-85503389</phone>
    <email>muzili63@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of oral and maxillofacial surgery, Huaxi university of medical science</name>
      <address>
        <city>Chendu</city>
        <state>Shichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Longjiang Li, Ph.D. , M.D</last_name>
      <phone>028-85503389</phone>
    </contact>
    <investigator>
      <last_name>longjiang Li, M.D., Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>April 6, 2012</last_update_submitted>
  <last_update_submitted_qc>April 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>p53 gene</keyword>
  <keyword>head and neck malignent tumors</keyword>
  <keyword>gene therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

